# A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

Study · id `cardio:ct-nct01810939` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01810939](<https://clinicaltrials.gov/study/NCT01810939>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01810939

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 243 participants.

## Technical summary

Registry record NCT01810939. Randomized; single masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2015-12-15.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 243 participants (enrolled count; ClinicalTrials.gov record NCT01810939, source copy `cardio:ctgov-nct01810939-2021-06-03`, retrieved 2026-10-26)
- Start date: 2013-02 (registry gives no type) (ClinicalTrials.gov record NCT01810939, source copy `cardio:ctgov-nct01810939-2021-06-03`, retrieved 2026-10-26)
- Primary completion: 2013-07 (actual) (ClinicalTrials.gov record NCT01810939, source copy `cardio:ctgov-nct01810939-2021-06-03`, retrieved 2026-10-26)
- Completion: 2013-08 (actual) (ClinicalTrials.gov record NCT01810939, source copy `cardio:ctgov-nct01810939-2021-06-03`, retrieved 2026-10-26)
- Results first posted: 2015-12-15 (ClinicalTrials.gov record NCT01810939, source copy `cardio:ctgov-nct01810939-2021-06-03`, retrieved 2026-10-26)
- Countries: United States; Croatia; Czechia; Denmark; Georgia; Hungary; Italy; Serbia; Slovenia; Ukraine (ClinicalTrials.gov record NCT01810939, source copy `cardio:ctgov-nct01810939-2021-06-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01810939-2021-06-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
- Acronym: OPAL
- Condition: Chronic Kidney Disease (CKD)
- Condition: Hyperkalemia (HK)
- Intervention (Drug): Patiromer
- Intervention (Drug): Placebo
- Lead sponsor: Relypsa, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Relypsa, Inc. (`cardio:org-relypsa-inc`)

## Provenance

Content hash: 2d491d2f1e1e6c2889bd283a66e10f89d4961a17d74a6cc3122b280b8ab0db5a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
